Robert Balk to Recombinant Proteins
This is a "connection" page, showing publications Robert Balk has written about Recombinant Proteins.
Connection Strength
0.086
-
New treatment strategies for severe sepsis and septic shock. Curr Opin Crit Care. 2003 Oct; 9(5):390-6.
Score: 0.056
-
Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med. 2003 Jun; 31(6):1612-9.
Score: 0.014
-
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997 Jul; 25(7):1115-24.
Score: 0.009
-
Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994 Jun 15; 271(23):1836-43.
Score: 0.007